Four months of rifampicin monotherapy for latent tuberculosis infection in children
Open Access
- 15 May 2022
- journal article
- review article
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 65 (5) , 214-221
Abstract
Diagnosing and treating latent tuberculosis infection (LTBI) is an important part of efforts to combat tuberculosis (TB). The Korean guidelines for TB published in 2020 recommend 2 LTBI regimens for children and adolescents: 9 months of daily isoniazid (9H) and 3 months of daily isoniazid plus rifampicin. Isoniazid for 6–12 months has been used to effectively treat LTBI in children for over 50 years. However, a long treatment period results in poor patient compliance. This review summarizes pediatric data on the treatment completion rate, safety, and efficacy of 4 months of daily rifampicin (4R) and evaluates the pharmacokinetics and pharmacodynamics of rifampicin in children. The 4R regimen has a higher treatment completion rate than the 9H regimen and equivalent safety in children. The efficacy of preventing TB is also consistent with that of 9H when summarizing reports published to date. A shorter treatment period could increase patient compliance and, therefore, prevent TB in more patients. By using an effective, safe, and highly compliant regimen for the treatment of children with LTBI, we would become one step closer to our goal of eradicating TB.Keywords
This publication has 61 references indexed in Scilit:
- Treatment of Latent Tuberculosis Infection in ChildrenJournal of the Pediatric Infectious Diseases Society, 2013
- Predictors of latent tuberculosis treatment initiation and completion at a U.S. public health clinic: a prospective cohort studyBMC Public Health, 2012
- Pharmacokinetics of Isoniazid, Rifampin, and Pyrazinamide in Children Younger than Two Years of Age with Tuberculosis: Evidence for Implementation of Revised World Health Organization RecommendationsAntimicrobial Agents and Chemotherapy, 2011
- Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosisBMC Medicine, 2009
- COMPLETION OF THERAPY FOR LATENT TUBERCULOSIS IN CHILDREN OF DIFFERENT NATIONALITIESThe Pediatric Infectious Disease Journal, 2008
- Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by RifampinAntimicrobial Agents and Chemotherapy, 2007
- RifampinPediatrics in Review, 2004
- Whither short-course chemotherapy?Respiratory Medicine, 1981
- Serum enzyme changes in patients receiving antituberculosis therapy with rifampicin or p-aminosalicylic acid, plus isoniazid and streptomycinTubercle, 1974
- A controlled clinical trial of daily and intermittent regimens of rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis in Hong Kong A Hong Kong tuberculosis treatment services/Brompton hospital/British medical research council investigationTubercle, 1974